investors.dexcom.comDexCom, Inc. Investor Relations

Overview News EventsPresentations Stock Info Stock Quote Stock Chart Historical Stock Quote Investment Calculator Financials Quarterly Results Annual Reports SEC Filings GovernanceSustainability Governance DocumentsSustainability Executive Management Board of Directors Committee Composition Resources Investor Email Alerts Investor ContactsAbout Dexcom NewsMediaCareers Search query Investor Relations Overview News EventsPresentations Stock Info Stock Quote Stock Chart Historical Stock Quote Investment Calculator Financials Quarterly Results Annual Reports SEC Filings GovernanceSustainability Governance DocumentsSustainability Executive Management Board of Directors Committee Composition Resources Investor Email Alerts Investor Contacts Corporate Overview DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. Learn moreOur Mission: Empowering People to Take Control of Health Press Releases View all news Featured Presentation Latest Events View All Events Sustainability Report Latest Financial Results View All Financial Results Proven Outcomes 1,2 Zero Fingersticks* Customizable AlertsAlarms Sharable Glucose Data and Device Connectivity Follow us IR Contacts Sean Christensen Vice President, Finance and Investor Relations Matt Carey Senior Investor Relations Manager (858) 200-0200 [email protected] Investor Email Alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. At DexCom, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to DexCom, Inc. to send you the requested Investor Email Alert updates. * Required Email Address * Investor Alert Options Investor Alert Options * News Quarterly Reports Annual Reports SEC Filings End of Day Stock Quote EventsPresentations Unsubscribe Email Alert Sign Up Confirmation 1. JAMA. 2017;317(4):371-378. 2. Welsh, J.B. et al (2019). "Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems." Diabetes Technol Ther 21(3) Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries. *If your glucose alerts and readings from the G6 or G7 CGM Systems do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions. Privacy Policy Terms of Use © Q4 Inc. - All rights reserved Powered By Q4 Inc. 5.122.0.3 (opens in new...